ScheBo® • M2-PK™ EDTA plasma test

The M2-PK recognizes the metabolic state of a wide variety of tumors and is a specific enzyme without organ specificity and therefore the marker of choice for a wide range of tumors

‍

Tumor cells express a characteristic isoform of the key enzyme pyruvate kinase. This isoenzyme M2-PK enters circulation and can be absorbed in EDTA plasma with the ScheBo^® • M2-PK™ EDTA plasma test be quantified. The development of M2-PK reflects the altered metabolic state of tumor cells. The test can therefore be used for various types of tumours. The concentration of M2-PK correlates very well with tumor malignancy (staging).

‍

Investigations into a variety of different human tumours show that in tumours, an isoenzyme of pyruvate kinase type M2 (M2-PK), occurs in increased concentration. There is a correlation between tumor malignancy and the content of the conceptually novel metabolic marker M2-PK.

‍

ScheBo^® • Biotech Has a Enzyme immunoassay (ELISA) developed, with which the M2-PK in EDTA plasma can be quantified. This test is based on two monoclonal antibodies that are highly specific for M2-PK are and therefore not with the other isoenzymes of pyruvate kinase (type L, R, M1 and M2) react.

First reliable metabolic marker for renal cell carcinoma:

In urology, the suitability of this novel metabolic marker has so far been clinically proven in renal cell carcinoma, among other things. Since M2-PK is a specific protein and has no organ specificity, the test can be used to support the diagnosis of various types of tumours.

‍

Sample material: EDTA plasma

‍

The ScheBo^® • M2-PK™ EDTA plasma test detects the following tumors:

• renal cell carcinoma
• lung carcinoma
• stomach carcinoma
• esophageal carcinoma
• cervical cancer
• breast cancer
• colorectal cancer
• pancreatic cancer
• ovarian cancer

When should M2-PK be determined in EDTA plasma:

• Treatment and follow-up

‍